about
UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at termEffects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomesMultidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane VesiclesABC drug transporter expression and functional activity in trophoblast-like cell lines and differentiating primary trophoblast.Improving the oral bioavailability of beneficial polyphenols through designed synergies.Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent.Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug.Drug transfer and metabolism by the human placenta.Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer.The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction.Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells.Heterocyclic cyclohexanone monocarbonyl analogs of curcumin can inhibit the activity of ATP-binding cassette transporters in cancer multidrug resistance.Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells.Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent.Identification of novel dietary phytochemicals inhibiting the efflux transporter breast cancer resistance protein (BCRP/ABCG2).Conformational and chemical requirements for antibody recognition of diphenylhydantoin derivatives.Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells.Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies.Human placental glucuronidation and transport of 3'azido-3'-deoxythymidine and uridine diphosphate glucuronic acid.3'-azido-3'-deoxythymidine (AZT) induces apoptosis and alters metabolic enzyme activity in human placenta.Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection.The effect of label affinity on the sensitivity and specificity of a hapten radioimmunoassay: a comparison of three [125I]diphenylhydantoin radioligands with the 14C-labelled drug.The effect of cimetidine, phenobarbitone and buthionine sulphoximine on the disposition of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in the rabbit.Pharmacokinetics and pharmacodynamics of chlorambucil delivered in long-circulating nanoemulsion.Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species.In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans.The effect of buthionine sulphoximine, cimetidine and phenobarbitone on the disposition of amsacrine in the rabbit.Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).High-throughput screening of potential inhibitors for the metabolism of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo.Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice.Non-specific binding of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in liver microsomes from various species.Dietary polyacetylenes of the falcarinol type are inhibitors of breast cancer resistance protein (BCRP/ABCG2).The evaluation of a radioimmunoassay for diphenylhydantoin using an iodinated tracer.Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide.Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
P50
Q28202360-11BBA108-28AD-4924-AAD5-68D6EF3403D9Q28345530-5F4A0100-5746-4010-A225-12C2EB7A35EBQ28546068-9B25B179-4C74-4793-98D5-C4F38795BC3CQ33228327-87CB7D4F-DF23-474B-88AB-81122128F8DDQ33646033-129A1E83-E5C5-4E7E-8F65-1AC9EC3C8F5DQ35027930-8237793B-F9C2-48F0-8F91-284CA32BEF99Q35163699-7FF1EA49-0D75-43DD-B11D-5FF0A47C752DQ35558002-E6816D2C-B8D8-4CC1-ADD8-6019791E6036Q35788063-4E1896E4-63F3-4A9E-B109-2CB5CA324FCCQ37740126-E0624929-B557-4874-B717-098EB4493A65Q38300490-D2B5F0EF-098E-40D0-80DB-442E5C43A7D2Q38787316-8BAA6FB9-1D01-44D7-88A7-92C4D8184A38Q38925066-D54C8B60-633B-48EB-BF0B-8F5633F03B38Q39014487-70F87CA7-CFE2-4B8E-B58D-97CC0C134B71Q39095954-C96D0CEB-62D8-4F58-A754-D3648E170052Q39180575-51FB7664-DBCE-4D00-AA95-6EAEDD188D98Q39417614-82A16F22-F2D8-443B-98DF-A73CEFB62E5AQ39626074-8EF75FAA-FF5D-43ED-9690-10BCD797E08EQ40530549-0FE2F07F-8D9B-4D5F-A5CE-64EA25DA78AFQ40534505-51EDDAEB-3F34-4AF1-9701-BB3598FA10A4Q40627465-9EDE634C-5739-4A8B-998F-42BC7A855B42Q40676305-F10933E1-F118-479F-B0A0-7E3EF03AB203Q41741682-7DE4BF34-3881-404D-A2E6-255E079300CBQ41933976-220F489F-9BE0-484C-82FE-14C08E018969Q43281343-BA94B860-02B6-453E-9485-A577C274CBA1Q43599993-CBDD1787-D32E-4849-87A0-91ED06393950Q43602586-4353715A-D56D-4DBD-9DB7-821AE232AE8FQ43679472-3FF832CC-629C-44D7-B5FC-DDE2BAE1CA8BQ43699660-AA7BABD8-07D2-4AE4-99C8-11B77748E2B6Q43745757-C67D7F88-A3AD-4EC5-A56E-D8ED5F782B90Q43893963-29EA1C9C-951F-4ACA-954A-A9633312BE49Q43894479-B2C9560F-F6B0-4B4C-9F74-8ED7FB2AE9C2Q43898845-59AE3F8C-92BF-4602-A511-85D05D72DA60Q44077254-293614F0-B9FA-4CE7-A622-E9091291856EQ44090052-E90E2464-B357-4408-9278-9462C0DDAB87Q44100976-95F338F6-3273-476B-89A5-BE0ED6FC9EE4Q44107338-B1226D62-3E7B-49F0-B41D-4ABA193E2997Q44119510-1F333162-678D-40B2-A554-2E23E39656F3Q44243172-16F6D3E9-ECF6-48CF-BE59-9DCE6267C459Q44461925-281F4ACE-C2DB-4DCD-82F4-5AE8C5F2D4E0
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
James W Paxton
@nl
James W Paxton
@sl
James W. Paxton
@en
James W. Paxton
@es
type
label
James W Paxton
@nl
James W Paxton
@sl
James W. Paxton
@en
James W. Paxton
@es
prefLabel
James W Paxton
@nl
James W Paxton
@sl
James W. Paxton
@en
James W. Paxton
@es
P106
P1153
7005717521
P21
P31
P496
0000-0002-2530-7047